If steps, exercise and daily routines are steady but weight is not shifting, this supports the idea of a plateau
Most symptoms occur during initial weeks and dose escalation, typically lessening as the body adapts
In the LEADER trial, Liraglutide demonstrated substantial cardiovascular and renal benefits in patients with Type 2 DM and CKD, while maintaining a favorable safety profile [91]
Pain reduction becomes significant
For patients having type-2 diabetes, semaglutide is often recommended when other forms of treatment are regarded as ineffective and other therapies are necessary
Energy Expenditure Enhancement: The glucagon component of this triple receptor agonist peptide increases resting body rate by 15-25%, providing a unique mechanism not available in GLP-1 or GLP-1/GIP mixes